AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023
Dec 13, 2023
31542_dirs_2023-12-13_c011b06c-816d-432f-9d30-d45ced3656a0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-12-11
Reporting Person: Miller Steve (Chief Op. & Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-12-11 | Common stock, par value $0.001 per share | M | 150000 | $1.13 | Acquired | 797457 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-11 | Options to purchase common stock | $1.13 | M | 150000 | Disposed | 2024-01-03 | Common Stock (150000) | Direct |
Footnotes
F1: Options vested in three annual tranches beginning on January 3, 2018.
More from CATALYST PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 11
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Regulatory Filings
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6
Director's Dealing
2025
Dec 30